Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Editor’s note: This is a developing news story. Please check back soon for updates.
Some patients with nonproliferative diabetic retinopathy had reduced vascular leakage or macular exudation after being treated orally with danegaptide, according to a study presented at Angiogenesis, Exudation, and Degeneration 2026.
Danegaptide (Breye Therapeutics) was well tolerated in the phase 1b study, paving the way for a phase 2 trial, according to a press release from Breye.
The results were presented by Carl D. Regillo, MD, director of the retina service at Wills Eye Hospital and a member of Breye’s